{
  "Country": "PO",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel",
      "Outcomes": "Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), safety, quality of life (EORTC QLQ-C30 and EORTC QLQ-LC13)."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nintedanib in combination with Docetaxel",
      "Outcomes": "Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), safety, quality of life (EORTC QLQ-C30 and EORTC QLQ-LC13)."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pemetrexed",
      "Outcomes": "Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), safety, quality of life (EORTC QLQ-C30 and EORTC QLQ-LC13)."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nivolumab",
      "Outcomes": "Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), safety, quality of life (EORTC QLQ-C30 and EORTC QLQ-LC13)."
    },
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy.",
      "Intervention": "New medicine under assessment",
      "Comparator": "Atezolizumab",
      "Outcomes": "Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), safety, quality of life (EORTC QLQ-C30 and EORTC QLQ-LC13)."
    }
  ],
  "SourceType": "hta_submission"
}